Showing results (281-290 of 976) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|February 18, 2022
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancerKirsten G M Aspros, Jodi M Carter, Tanya L Hoskin, et al.
NPJ Breast Cancer|March 15, 2022
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savingsPo-Hung Hsieh, Alec J Kacew, Marie Dreyer, et al.
NPJ Breast Cancer|March 23, 2022
Do current family history-based genetic testing guidelines contribute to breast cancer health inequities?Samantha H Jakuboski, Jasmine A McDonald, Mary Beth Terry
NPJ Breast Cancer|June 27, 2017
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohortXavier Pivot, Gilles Romieu, Pierre Fumoleau, et al.
NPJ Breast Cancer|June 27, 2017
Vitamin D ointment for prevention of radiation dermatitis in breast cancer patientsNicola J Nasser, Shlomit Fenig, Amiram Ravid, et al.
NPJ Breast Cancer|June 27, 2017
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancerJeffrey P Solzak, Rutuja V Atale, Bradley A Hancock, et al.
NPJ Breast Cancer|June 27, 2017
Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivoJason J Zoeller, Roderick T Bronson, Laura M Selfors, et al.
NPJ Breast Cancer|July 8, 2017
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapyYu-Hsiang Chen, Bradley A Hancock, Jeffrey P Solzak, et al.
NPJ Breast Cancer|July 11, 2017
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)Minetta C Liu, Brandelyn N Pitcher, Elaine R Mardis, et al.
NPJ Breast Cancer|August 22, 2020
Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancerOlga Kantor, Stephanie Wong, Anna Weiss, et al.
Pageof 98